Minqi Chen, Wanchao Hou, Jinhua Lu, Qianhan Liu, Wanrong Zeng, Erwei Hao, Xiaotao Hou, Zhengcai Du, Jiagang Deng, Kai Yu
2026.2.1Current Pharmaceutical Analysis
要旨
Fibrosis is a dynamic yet a stage that poses therapeutic challenges in chronic liver diseases and other systemic disorders. Huanggen (HG), the dried root of Prismatomeris connata or Prismatomeris tetrandra , has long been used in Zhuang traditional medicine to treat hepatitis, silicosis, rheumatism, and other chronic conditions. Modern studies reveal a diverse chemical profile, including anthraquinones, triterpenes, polysaccharides, and trace organometallics, which contribute to its pharmacological activities. HG exerts antitumor, anti-inflammatory, and antioxidant effects; suppresses hepatic stellate cell activation; inhibits epithelial-mesenchymal transition; and regulates macrophage polarization through modulation of TGF-β/Smad, PI3K/Akt, Nrf2/HO-1 pathways, as well as oxidative stress and immune responses. This review integrates phytochemistry, pharmacology, and mechanistic insights into HG, with a particular focus on its role in hepatic and pulmonary fibrosis, aiming to provide a foundation for the development of novel antifibrotic therapeutics.
引用形式
CHEN, Minqi, et al. Pharmacological basis and antifibrotic potential of zhuang medicine huanggen in hepatic and pulmonary fibrosis. Current Pharmaceutical Analysis, 2026, 22(3): 211–218.